CE Pricing / Flex Credit

Add to Cart
Save with tiered CE Pricing
Starts at $9.98 per contact hour
Min. Hours $$/Hr
4 hours $8.98
8 hours $7.98
12 hours $6.98
20 hours $5.98
30 hours $4.98

Find CE Courses

Prevention of Neonatal Group B Streptococcal Infection

2.0 Contact Hours / 0.20 AOTA CEUs
Target Audience: Nurses, healthcare professionals, and interested individuals
Purpose/Goal: The goal of this course is to provide health care professionals with an overview of this disease. Topics covered include its incidence, consequences, risk factors, and types. The latest recommendations by the American College of Obstetricians and Gynecologists (ACOG), the Centers for Disease Control and Prevention (CDC), and the American Academy of Pediatrics (AAP) are also presented.
$19.96
Add to Cart

Description

Great strides have been made in preventing and treating neonatal group B streptococcal infection during the last few decades, especially with the use of prophylactic antibiotics during labor. In addition, the development of rapid detection tests and a vaccine look promising. This course will examine the incidence, risk factors, consequences, and treatment guidelines for Group B streptococcal infection.

Objectives

Upon completion of the course, you will be able to do the following:

  • Describe the impact of group B streptococcal (GBS) disease on the newborn.
  • State the incidence of GBS in the United States.
  • Describe how GBS is transmitted from mother to baby.
  • Describe the two major types of GBS disease.
  • List maternal consequences of GBS disease.
  • List fetal consequences of GBS disease.
  • Identify risk factors for early-onset GBS disease.
  • Describe key considerations for collecting and processing vaginal and rectal cultures of GBS.
  • Compare and contrast the screening strategy with the risk factor strategy in treating GBS.
  • Explain the updated recommendations for preventing perinatal GBS disease.
  • Describe the key issues in the recommendations for managing a newborn whose mother received intrapartum antimicrobial agents to prevent GBS or suspected chorioamnionitis.
  • State the recommendations for intrapartum antimicrobial prophylaxis for GBS prevention.
  • State the adverse effects and potential complications of chemoprophylaxis in GBS treatment.
  • Identify future trends in GBS prevention and treatment.

Criteria for successful completion

Complete the course post exam (CE Test) with a score of 80% or greater. Complete all fields of the course evaluation form. Certificate of Completion is provided once the course post exam is passed per criteria above.

Accredited By

  • American Board of Managed Care Nursing
    The American Board of Managed Care Nursing recognizes all of ALLEGRA Learning Solutions' ANCC accredited courses for continuing education credit for Certified Managed Care Nurses (CMCNs).
  • ANCC - American Nurses Credentialing Center
    ALLEGRA Learning Solutions, LLC is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
  • ASWB - Association of Social Work Boards
    This course is approved by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program to be offered by ALLEGRA Learning Solutions, LLC as an individual course. Individual courses, not providers, are approved at the course level. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. ACE course approval period: 04/22/2021-04/22/2024. Social workers completing this course receive the specified distance learning continuing education credits.
  • California Board of Behavioral Sciences
    California Board of Behavioral Sciences Provider Number PCE 1564. Course meets the qualifications for the stated hours of continuing education credit for MFTs and/or LCSWs as required by the California Board of Behavioral Sciences.
  • California Board of Registered Nursing
    ALLEGRA Learning Solutions is approved by the California Board of Registered Nursing, Provider # CEP 14693 for the number of hours stated.
  • California Department of Health, Aid, and Technician Certification Section
    The California Department of Health, Aid, and Technician Certification Section accepts continuing education offered by CA-BRN approved providers.
  • District of Columbia Board of Nursing
    ALLEGRA Learning Solutions (CE Provider # 50-12076) submits all continuing education records to CE BROKER after successful completion.
  • Florida Board of Nursing
    ALLEGRA Learning Solutions, LLC is accredited as a provider of continuing education by the Florida Board of nursing (CE Provider # 50-12076). Courses are automatically submitted to CE Broker.
  • Florida Board of Nursing - Certified Nursing Assistants
    ALLEGRA Learning Solutions (CE Broker Provider # 50-12076) submits all continuing education records to CE Broker after successful completion.
  • Florida Board of Respiratory Care
    ALLEGRA Learning Solutions, LLC is accredited as a provider of continuing education by the Florida Board of Respiratory Care
  • Florida Council of Dietetics and Nutrition
    ALLEGRA Learning Solutions, LLC is accredited as a provider of continuing education by the Florida Council of Dietetitics and Nutrition
  • Florida Council of Licensed Midwifery
    ALLEGRA Learning Solutions, LLC is accredited as a provider of continuing education by the Florida Council of Licensed Midwifery
  • NAADAC - The National Association of Alcohol and Drug Abuse Counselors
    This course has been approved by ALLEGRA Learning Solutions, LLC, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #813, ALLEGRA Learning Solutions, LLC is responsible for all aspects of their programming.
  • NCBTMB -National Certification Board for Therapeutic Massage & Bodywork
    ALLEGRA Learning Solutions, LLC is approved by the National Certification Board for Therapeutic Massage & Bodywork (NCBTMB) as a continuing education Approved Provider. Provider Number 451562-11.
  • Florida Board of Massage Therapists
    ALLEGRA Learning Solutions, LLC is accredited as a provider of continuing education by the Florida Board of Massage Therapists
  • AOTA - American Occupational Therapy Association
    ALLEGRA Learning Solutions, LLC, is an approved provider of continuing education for occupational therapists by the American Occupational Therapy Association. Approved Provider # 3166

Other Details

Course Expires:

July 06, 2024

Instructor(s):
  • Cyndie Koopsen, RN, BSN, MBA, HNB-BC, RN-BC, HWNC-BC
  • Caroline Young, MPH
Jurisdictional Requirements:

Continuing education (CE) licensing requirements vary by jurisdiction, are not well defined, and may change. These CE requirements may vary in terms of the number of hours required to the types of courses that must be taken. ALLEGRA Learning Solutions, LLC recommends you contact your licensing board or accrediting organization for the latest continuing education requirements of your state or territory. Compliance with CE requirements is the responsibility of the individual health care provider. Health care providers must understand the CE requirements in their jurisdictions, and be sure they are up-to-date on any rule changes that affect their license. For further information, please see our Accreditation Information.

Accommodations for Disabilities:

Every effort will be made to accommodate your special needs. To request accommodations, please contact us.

Conflicts of Interest and Relevant Financial Relationships:

The authors/planning committee members have no conflicts of interests or relevant financial relationships to declare relevant to this activity.

Commercial Support:

No commercial support has been received for this activity.

Non-endorsement of products:

Accreditation refers to recognition of continuing nursing education only and does not imply ALLEGRA Learning Solutions, LLC approval or endorsement of any commercial product.

Off-label Use of Products:

None of the authors intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Cart

0.0
Hrs